Summary
Prosthetic hip joints consist of two components: the femoral component and the articular interface; each of which may be metallic or non-metallic. Metal-on-metal (MOM) prostheses were previously considered to offer improved durability, and have in the past been suggested for hip replacements in younger patients. However, an analysis of data from the National Joint Registry of England and Wales showed poor implant survival for MOM-stemmed prostheses compared with other materials.
MOM prostheses of cobalt and chromium have been associated with high blood concentrations of these metals, and current UK guidelines recommend post-operative monitoring in recipients of a MOM implant. Cobalt and chromium ions cross the placenta and concern has therefore been expressed about potential adverse effects on the developing fetus.
The available data provide no indication of an increased risk of congenital malformation in infants born to women with MOM hip prostheses, but are too limited to conclude that there is no increase in risk. Data on other adverse pregnancy outcomes are too limited to permit an evidence-based risk assessment. Additional fetal monitoring may be advisable in cases of high maternal blood concentrations of cobalt or chromium. Other risk factors may also be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments. Discussion with UKTIS is recommended in all cases, but particularly where there is associated maternal toxicity and/or high blood cobalt and chromium concentrations.
This document is regularly reviewed and updated. Only use full UKTIS monographs downloaded directly from TOXBASE.org to be sure you are using the most up-to-date version. The summaries of these monographs are openly available on UKTIS.org.
Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from TOXBASE.org or UKTIS.org to ensure you are using the most up-to-date version.